Information Provided By:
Fly News Breaks for November 8, 2016
RARE
Nov 8, 2016 | 07:38 EDT
Canaccord analyst Arlinda Lee lowered her price target on Ultragenyx to $108 from $120 due to an expected increase in R&D spending after the company reported pipeline progress on four clinical candidates and said it expects to file for U.S. KRN23 pediatric approval earlier than expected in the second half of 2017. Lee reiterated her Buy rating on Ultragenyx shares as she expects regulatory approvals in 2017, while also citing its attractive pipeline.
News For RARE From the Last 2 Days
There are no results for your query RARE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.